Following my earlier post on this issue, it is now reported that the Indian Patent Office (IPO) has refused patent to the anti-cancer drug, Abraxane. I am yet to obtain a copy of this IPO order.
A recap
Briefly, the opposition against the patent application for Abraxane was filed by Natco Pharma with the IPO and was decided against the patent applicant, Abraxis Biosciences (“Abraxis”). Abraxis appealed against the IPO’s order with the Intellectual Property Appellate Board (IPAB) owing to certain procedural lapses. IPAB agreed with Abraxis and asked the IPO to consider the opposition afresh.
What’s new?
The recent order of the IPO is said to have stated the following:
“The amended claims (here Abraxis Boisciences) lack inventive step and do not constitute an invention under the Patents Act, 1970.”
I will update this post and discuss the IPO’s order in detail once I peruse the order.
Raja Selvam
Founder & Managing Attorney, Selvam & Selvam | Practice areas include Trademarks, Patents, Domain names & Business law. Visiting faculty, Department of Journalism, Madras University where I teach copyrights & trademarks law. Passionate about entrepreneurship, start-ups, stocks, farming, technology and law.
Empire strikes again – Indian Trademark Office issues notice regarding non filing of reply to examination report & counter statement to oppositions
In a welcome move, the Indian Trademark Office (TMO) issued a public notice via Trade Marks Journal No. 2090 dated February 6, 2022, whereby the…
The battle of the ‘JABARDASTH’ vs ‘BAND BAJA BAARAAT’
On July 8, 2019 The Delhi High Court decided that a copyright infringement occurs when there is no ‘Originality’ under Section 13(3)(a) and Section…
Service of notice is completed when it is received by the party, not as soon as it is sent by the Trade mark office
When a trademark application is filed and subsequently accepted by the Trademark Office, it doesn't mean an immediate registration. Instead, the…